Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U03 Substudy 03C: belzutifan plus zanzalintinib in recurrent renal cell carcinoma after adjuvant PD-1/PD-L1 therapy
MOH_2025-06-04_014074Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of belzutifan and zanzalintinib in renal cell carcinoma (RCC) (3 cohorts), sponsored by Merck & Co. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
belzutifanzanzalintinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on MOH_2025-06-04_014074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-04_014074.